Key statistics
As of last trade Belite Bio Inc (D01:FRA) traded at 152.00, -7.32% below its 52-week high of 164.00, set on Feb 03, 2026.
52-week range
| Open | 152.00 |
|---|---|
| High | 152.00 |
| Low | 152.00 |
| Bid | 148.00 |
| Offer | 159.00 |
| Previous close | 151.00 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 37.51m |
| Free float | 34.41m |
| P/E (TTM) | -- |
| Market cap | 6.87bn USD |
| EPS (TTM) | -1.55 USD |
Data delayed at least 15 minutes, as of Feb 10 2026 07:10 GMT.
More ▼
Announcements
- Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO)
- Belite Bio Completes Enrollment in the DRAGON II Clinical Trial of Tinlarebant for Stargardt Disease (STGD1)
- Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares
- Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
- New Hope for People Living with a Disease Once Deemed Untreatable: Belite Bio Announces Positive Topline Results from the Pivotal Global, Phase 3 DRAGON Trial of Tinlarebant in Adolescents with Stargardt Disease
- Belite Bio Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
- Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results
- Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
- Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
- Belite Bio to Participate in the 2025 Maxim Growth Summit
More ▼
